Close this search box.


Leaders in clinical and translational cancer research from academia, industry, government and nonprofit advocacy sectors convene each spring in Bethesda, Maryland, for the AAADV Workshop, a unique forum designed to speed cancer treatments to patients. This four-day, Virtual interactive workshop offers a mix of small group lectures, moderated discussions, plenary lectures and facilitated case studies of successful drug applications. Participants gain valuable insights on negotiating the spectrum of successful drug development and hone their strategic planning skills with a focus on target validation and pathway identification. AAADV is the only workshop held in collaboration with the U.S. Food and Drug Administration designed specifically to help participants understand and negotiate the drug development approval process so effective cancer treatments can reach patients more quickly.


About 10 million people will die from cancer this year. Between 30–50% of these cancer cases are preventable, highlighting that prevention remains the most cost-effective long-term strategy for the control of cancer. Consequently, the World Health Organization (WHO) proposes to strengthen national policies and programs to raise awareness, reduce exposure to cancer risk factors, and ensure that people are provided with the information and support they need to adopt healthy lifestyles to reduce their risk of cancer.

One of the most prominent national programs is the United States (US) President Biden and First Lady Biden’s Cancer Moonshot℠ , which has set a goal of reducing the cancer death rate in the US by at least 50% over the next 25 years. Researchers from the US National Institutes of Health (NIH) recently reported that achieving this goal will require increased access to and use of interventions known to prevent common causes of cancer death (Cancer Discovery April 17, 2023).

The program committee of the AAADV-ASCO-CDDF Workshop on Global Cancer Drug Development recognizes that the decades long investment in cancer research has resulted in unprecedented knowledge and opportunity in intervention in the cancer trajectory. Nonetheless, much anti-cancer agent development is focused on cancer therapies. The potential impact of exploiting the vulnerabilities of pre-malignant cells and conditions to prevent cancer is an additional opportunity to reduce the cancer burden. Unfortunately, the development and clinical evaluation of novel cancer prevention strategies remains challenging.

In 2023, the AAADV-ASCO-CDDF Workshop on Global Cancer Drug Development will continue it’s focus on global cancer drug development, but will strategically emphasize the potential and opportunities for proven and novel cancer prevention strategies. Experts from academic, commercial, and government will present and discuss the current cancer prevention landscape, the opportunities for impactful interventions that will prevent cancer morbidity and mortality, and discuss challenges and opportunities in the clinical development and delivery of these novel agents.


Scholarships covering the cost of registration, travel and accommodations for the Pre-Workshop for Patient Advocate attendees are available.

Participants Will:​

  • Examine the most urgent issues and meaningful trends in anticancer agent development and validation.
  • Learn new approaches for diagnosing, treating and preventing cancer.
  • Benefit from a mix of small group lectures, moderated discussions, facilitated case studies of successful new drug applications and plenary lectures.
  • Network with researchers, regulators, patient advocates and others working on the front lines of cancer research and treatment.
  • Have access to video recorted sessions and material. 

Special Features

Case studies of successful new drug applications feature pharmaceutical drug development teams and U.S. Food and Drug Administration officers involved in the drug approval process. Four drugs will be presented twice over the course of the Workshop.

The AAADV Workshop In-Depth Discussion Groups offer moderated sessions on numerous topics, each presented by a panel including researchers from academia, industry and the U.S. Food and Drug Administration, as well as patient advocates, giving attendees a rare opportunity to interact with and question numerous experts in a given field of study. Attendees will choose one of five topics, presented concurrently, to attend each day.

The Core Curriculum is designed for early-career drug development investigators and covers all aspects of clinical studies: pre-clinical and clinical science, statistical structure of trials, ethical requirements and regulatory considerations. It is taught by U.S. Food and Drug Administration (FDA) medical officers and senior scientists. Core Curriculum sessions occur concurrently with AAADV Workshop morning sessions on May 5, and offer breakfast discussion groups May 5-8.

Satellite Sessions are additional meetings or presentations held the afternoon of May 8 after conclusion of the AAADV Workshop. Visit back for details and room locations. 

Executive Committee

H. Kim Lyerly, MD

Duke University

Richard Schilsky, MD

Professor emeritus
University of Chicago

Renzo Canetta, MD

Independent Consultant.

Thomas Fleming, PhD​

Thomas Fleming, PhD

Professor, Department of Biostatistics University of Washington School of Medicine

2023 Sponsors